Abstracts tagged "Anxiety"

Abstract Number: 607 • 2017 ACR/ARHP Annual Meeting
Secukinumab Treatment of Psoriatic Arthritis and Moderate to Severe Psoriasis Relieves Anxiety/Depression up to 52 Weeks: An Overview from Secukinumab Phase 3 Clinical Trials
Philip J Mease¹, Mark Lebwohl², Isabelle Gilloteau³, Todd Fox³, Jaime Oliver³, Steffen Jugl³ and Alice B Gottlieb⁴, ¹University of Washington School of Medicine and Swedish Medical Center, Seattle, WA, ²Icahn School of Medicine at Mount Sinai, New York, NY, ³Novartis Pharma AG, Basel, Switzerland, ⁴Department of Dermatology, New York Medical College, Vallhalla, NY
Background/Purpose: Secukinumab (SEC), a fully human monoclonal antibody selectively neutralizing interleukin-17A, exhibits significant efficacy, with a favorable safety profile, in the treatment of psoriatic arthritis…
Abstract Number: 847 • 2017 ACR/ARHP Annual Meeting
The Mediational Role of Helplessness in Psychological Outcomes in Systemic Lupus Erythematosus
Desiree R Azizoddin¹, Sarah D. Mills², Perry M. Nicassio³, Geraldine Zamora Racaza⁴ and Michael Weisman⁵, ¹1611 W Harrison, 1611 W Harrison, Chicago, IL, ²SDSU/UC San Diego Joint Doctoral Program in Clinical Psychology, San Diego, CA, ³Cousins Center for PNI, UCLA, LA, CA, ⁴Division of Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ⁵Cedars-Sinai Medical Center Division of Rheumatology, Los Angeles, CA
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic, autoimmune disease affecting multiple organs, leading to a significant impact on health-related quality of life. Theoretical models…
Abstract Number: 2528 • 2017 ACR/ARHP Annual Meeting
Prevalence of Depression and Attention Deficit Hyperactivity Disorder in Female Patients at a Combined Psoriasis-Psoriatic Arthritis Center
Soumya M. Reddy¹, Rebecca Haberman², Eileen Lydon³, Andrea L. Neimann⁴, Malavika Attur³, Mark Butler⁵, Tanya M. Spruill⁵ and Jose U. Scher⁶, ¹Department of Medicine, Division of Rheumatology *contributed equally, New York University School of Medicine, New York, NY, ²Department of Medicine (*contributed equally), New York University School of Medicine, New York, NY, ³Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ⁴Department of Dermatology, New York University School of Medicine, New York, NY, ⁵Department of Population Health, New York University School of Medicine, New York, NY, ⁶New York University School of Medicine, New York, NY
Background/Purpose: Psoriatic arthritis (PsA) is a heterogeneous inflammatory arthritis affecting multiple clinical domains. Untreated, PsA has the potential for significant morbidity and disability. Psychiatric disorders…
Abstract Number: 2040 • 2016 ACR/ARHP Annual Meeting
Responsiveness of Patient Reported Outcomes Measurement Information System Measures in RA Patients Starting or Switching a DMARD
Alyssa Wohlfahrt¹, Clifton Bingham III², Zhi Zhang¹, Marcy Bolster³, Larry W. Moreland⁴, Tuhina Neogi⁵, Kristine Phillips⁶ and Yvonne C. Lee⁷, ¹Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ²Johns Hopkins University, Baltimore, MD, ³Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Boston, MA, ⁴Rheumatology & Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ⁵Clinical Epidemiology, Boston University School of Medicine, Boston, MA, ⁶Rheumatology, University of Michigan, Ann Arbor, MI, ⁷Rheumatology Immunology & Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: The Patient Reported Outcome Measurement Information System (PROMIS) is an NIH-developed metric for assessing multidimensional aspects of health across different conditions. Prior RA studies…
Abstract Number: 3085 • 2016 ACR/ARHP Annual Meeting
Do Depression and Anxiety Reduce the Chance of Remission in Rheumatoid Arthritis and Psoriatic Arthritis?
Brigitte Michelsen^1,2, Karen M Fagerli¹, Elisabeth Lie¹, Hilde Berner Hammer³, Glenn Haugeberg^4,5, Eirik K Kristianslund¹ and Tore K. Kvien¹, ¹Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ²Dept. of Rheumatology, Hospital of Southern Norway Trust, Kristiansand, Norway, ³Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁴Dept. of Rheumatology, Martina Hansens Hospital, Bærum, Norway, ⁵Dept. of Rheumatology, The Norwegian University of Science and Technology, Trondheim, Norway
Background/Purpose: Depression and anxiety are reported to predict poorer treatment outcomes in rheumatoid arthritis (RA).1 Whether this can be confirmed in larger, prospective studies as…
Abstract Number: 3234 • 2016 ACR/ARHP Annual Meeting
Prevalence and Metric of Depression and Anxiety in Lupus: A Systematic Review and Meta-Analys
Ahmed Moustafa¹, Mohamed Hassanein², Lihi Eder³, Joan E. Wither⁴, William Fung⁵, Panayiotis Lambiris⁶ and Zahi Touma⁴, ¹Medicine, Western University, London, ON, Canada, ²Michigan State University, East Lansing, MI, ³Medicine, University of Toronto, Women's College Hospital, Toronto, ON, Canada, ⁴Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁵Medicine, University of Toronto, Toronto, ON, Canada, ⁶University Health Network, Toronto, ON, Canada
Background/Purpose: To systematically review the literature on the: 1) prevalence of depression and anxiety in SLE patients and 2) metrics of depression and anxiety. …
Abstract Number: 1514 • 2016 ACR/ARHP Annual Meeting
Symptoms of Depression and Anxiety Predict Worse Disease Activity and Functional Disability in a Cohort of Established Rheumatoid Arthritis Patients
Christine Iannaccone¹, Taysir G. Mahmoud², Jing Cui³, Michael Weinblatt¹ and NA Shadick⁴, ¹Rheumatology, Immunology and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ²Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ³Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁴Rheumatology Immunology & Allergy, Brigham & Women's Hosp, Boston, MA
Background/Purpose: Depression and anxiety disorders are common in RA patients, with the most recent prevalence estimates indicating that 16.8% of RA patients have a diagnosis…
Abstract Number: 1525 • 2016 ACR/ARHP Annual Meeting
Pain, Physical Function, and Worry (But Not Depression and Poor Sleep) Lead to Greater Fatigue in RA
Susan J. Bartlett¹, Michelle Jones² and Clifton Bingham III³, ¹Department of Medicine, Division of ClinEpi, Rheumatology, Respirology, McGill University, Montreal, QC, Canada, ²Johns Hopkins University School of Medicine, Baltimore, MD, ³Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Some view fatigue as resulting from disease activity, while others see it as a natural consequence of the pain, disability, and the emotional burden…
Abstract Number: 1539 • 2016 ACR/ARHP Annual Meeting
Physician-Reported and Patient-Reported Anxiety and Depression in Rheumatoid Arthritis
Nan Li¹, Emma Sullivan², Stuart Blackburn², Danuta Kielar¹ and Steve Peterson¹, ¹Janssen Research & Development, LLC, Spring House, PA, ²Adelphi Real World, Manchester, United Kingdom
Background/Purpose: As many as 40% of people with rheumatoid arthritis (RA) experience significant symptoms of mood disorders. In addition to the pain, fatigue, and disability…
Abstract Number: 1701 • 2016 ACR/ARHP Annual Meeting
The Presence of Depression Might be an Important Determinant of Achieving Minimal Disease Activity State in Psoriatic Arthritis
Agnes Szentpetery¹, Natsumi Ikumi¹, Brian Kirby² and Oliver FitzGerald³, ¹St. Vincent's University Hospital, Department of Rheumatology, Dublin, Ireland, ²St. Vincent's University Hospital, Department of Dermatology, Dublin, Ireland, ³St. Vincent's University Hospital, Department of Rheumatology. UCD Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Dublin, Ireland
Background/Purpose: Depression and anxiety are well known comorbidities in psoriasis (PsO) and psoriatic arthritis (PsA) with higher prevalence in PsA. Patients with PsA have…
Abstract Number: 44 • 2015 ACR/ARHP Annual Meeting
The Prevalence of Depression and Anxiety in a Cross-Section of Rheumatological Conditions
Faith Matcham¹, Nicola J. Gullick², Matthew Hotopf³, Sam Norton⁴, Sophia Steer⁵ and James Galloway⁶, ¹Psychological Medicine Clinical Academic Group, King's College London, London, United Kingdom, ²Rheumatology, Department of Rheumatology, King`s College Hospital NHS Foundation Trust, London, United Kingdom, ³Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, United Kingdom, ⁴Institute of Psychiatry, King's College London, London, United Kingdom, ⁵Rheumatology Dept, Kings College Hospital, London, United Kingdom, ⁶Academic Department of Rheumatology, King´s College London, London, United Kingdom
Background/Purpose: Depression and anxiety have detrimental effects on quality-of-life, treatment response and disease outcomes. Whilst psychological morbidity has been described in individual rheumatic diseases, less…
Abstract Number: 422 • 2015 ACR/ARHP Annual Meeting
Mood Disorder Is Highly Prevalent in a Multi-Ethnic Urban Pediatric Lupus Cohort
Tamar Rubinstein^1,2, Dawn Wahezi^1,2, Jay Mehta^3,4, Norman Ilowite^3,5, Debbie Rybak⁶, Jordan Brodsky⁶, Nicole Jordan⁶, Ruth Stein^5,7 and Chaim Putterman⁶, ¹Pediatric Rheumatology, Albert Einstein College of Medicine, Bronx, NY, ²Pediatric Rheumatology, Children's Hospital at Montefiore, Bronx, NY, ³Division of Pediatric Rheumatology, Children's Hospital at Montefiore, Bronx, NY, ⁴Division of Pediatric Rheumatology, Albert Einstein College of Medicine, Bronx, NY, ⁵Pediatrics, Albert Einstein College of Medicine, Bronx, NY, ⁶Division of Rheumatology, Albert Einstein College of Medicine, Bronx, NY, ⁷Pediatrics, Children's Hospital at Montefiore, Bronx, NY
Background/Purpose: While mood disorder, most commonly manifesting as depression and anxiety symptoms, is often reported in pediatric lupus patients, prevalence rates vary widely. Many published…
Abstract Number: 655 • 2015 ACR/ARHP Annual Meeting
Rasch Analysis of the Hospital Anxiety and Depression Scale in Psoriatic Arthritis: Results from the Presta Study.
Mwidimi Ndosi¹, Ming-Anne Hsu², J. Cappelleri³, Heather Jones⁴, Amit Chhabra⁵ and Philip S. Helliwell⁶, ¹School of Healthcare, University of Leeds, Leeds, United Kingdom, ²445 Eastern Point Road, Pfizer Inc, Groton, CT, ³Statistics, Pfizer Inc, New London, CT, ⁴Inflammation Global Medical Affairs, Pfizer, Collegeville, PA, ⁵Pfizer Inc, Collegeville, PA, ⁶Section of Musculoskeletal Disease, University of Leeds, Leeds, United Kingdom
Background/Purpose: The Hospital Anxiety and Depression Scale (HADs) is a generic measure of psychological status comprising anxiety and depression subscales. The aim of this study…
Abstract Number: 917 • 2015 ACR/ARHP Annual Meeting
Chronic Widespread Pain in Adolescents Is Highly Associated to Stress and Anxiety
Stefan Bergman^1,2,3, Ann Bremander^1,3,4, Anna-Carin Bergman⁵ and Sofia Brorsson⁶, ¹FoU Spenshult, Halmstad, Sweden, ²Primary Health Care Unit, Department of Public Health and Community Medicine, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden, ³Department of Clinical Sciences, Lund, Section of Rheumatology, Lund University, Lund, Sweden, ⁴School of Business, Engineering and Science, Halmstad University, Halmstad, Sweden, ⁵Sannarpsgymnasiet, Halmstad, Sweden, ⁶Health and Welfare, Dalarna University, Falun, Sweden
Background/Purpose: Chronic widespread pain (CWP), one of the hallmarks of fibromyalgia, is not uncommon in adolescents and it has previously been shown that adolescents with…
Abstract Number: 998 • 2015 ACR/ARHP Annual Meeting
A Psychometric Analysis of the Social Interaction Anxiety Scale (SIAS-6) in Systemic Sclerosis: Results from the Scleroderma Patient-Centered Intervention Network (SPIN) Cohort
Shadi Gholizadeh¹, Sarah D. Mills², Rina S. Fox², Lisa Jewett^3,4, Linda Kwakkenbos^3,4, Marie-Eve Carrier⁵, Brett D. Thombs^3,5, Scott C. Roesch^2,6, Vanessa L. Malcarne^2,6, Karen Gottesman⁷ and SPIN Investigators, ¹Psychoogy, SDSU/UC San Diego Joint Doctoral Program in Clinical Psychology, San Diego, CA, ²SDSU/UC San Diego Joint Doctoral Program in Clinical Psychology, San Diego, CA, ³McGill University, Montreal, QC, Canada, ⁴Lady Davis Institute for Medical Research, Jewish General Hospital, Montréal, QC, Canada, ⁵Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, QC, Canada, ⁶Psychology, San Diego State University, San Diego, CA, ⁷Scleroderma Foundation, Los Angeles, CA
Background/Purpose: The experience of living with a serious illness, such as systemic sclerosis (SSc), can pose challenges for an individual’s self-concept and social roles. This…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.